This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Resistance Training in Lung Cancer Patients on Chemotherapy

This study has been completed.
Information provided by (Responsible Party):
Kristina Karvinen, East Carolina University Identifier:
First received: January 6, 2010
Last updated: August 19, 2015
Last verified: August 2015
The purpose of this study is to examine the effectiveness of a resistance training program on reducing systemic inflammation and improving chemotherapy completion in lung cancer patients being treated with curative intent chemotherapy.

Condition Intervention
Inflammation Lung Cancer Behavioral: Exercise

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Effectiveness of a Resistance Training Program on Inflammatory Markers and Chemotherapy Completion in Lung Cancer Patients on Chemotherapy

Resource links provided by NLM:

Further study details as provided by Kristina Karvinen, East Carolina University:

Primary Outcome Measures:
  • Systemic inflammation measured by c-reactive protein. [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Chemotherapy completion [ Time Frame: 12 weeks ]

Enrollment: 15
Study Start Date: January 2010
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Resistance training
Group assigned to complete resistance training during duration of chemotherapy.
Behavioral: Exercise
Resistance training with resistance bands.
No Intervention: Control
Usual care.


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically diagnosed with lung cancer
  • Stage I, II, or III
  • Eligible for chemotherapy with curative intent
  • 21 years of age or older
  • Approval to participate in study by treating oncologist or family physician

Exclusion Criteria:

  • Unstable cardiac disease
  • Untreated bone or brain metastases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01130714

United States, North Carolina
Leo Jenkins Cancer Center
Greenville, North Carolina, United States, 27834
Sponsors and Collaborators
East Carolina University
Principal Investigator: Kristina H Karvinen, PhD East Carolina University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Kristina Karvinen, Assistant Professor, East Carolina University Identifier: NCT01130714     History of Changes
Other Study ID Numbers: UMCIRB 09-0725
Study First Received: January 6, 2010
Last Updated: August 19, 2015

Keywords provided by Kristina Karvinen, East Carolina University:
lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Pathologic Processes processed this record on August 23, 2017